




RealRate

PHARMACEUTICAL 2015

Nektar Therapeutics
Rank 208 of 274

NEKTAR®



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Nektar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nektar Therapeutics compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 8.3% points. The greatest weakness of Nektar Therapeutics is the variable Other Liabilities, reducing the Economic Capital Ratio by 161% points.

The company's Economic Capital Ratio, given in the ranking table, is 147%, being 107% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	288,200
Cost of Goods Sold	0
Intangible Assets	76,501
Liabilities, Current	64,047
Liabilities, Non-Current	14,721
Other Assets	6,552
Other Compr. Net Income	0
Other Expenses	28,021
Other Liabilities	326,521
Other Net Income	-37,943
Other Revenues	200,707
Property and Equipment	70,368
Research and Development	147,734
Selling, General and Administrative Expense	40,925

Output Variable	Value in 1000 USD
Assets	441,621
Liabilities	405,289
Expenses	216,680
Revenues	200,707
Stockholders Equity	36,332
Net Income	-53,916
Comprehensive Net Income	-53,916
BaseVar	651,120
ECR before LimitedLiability	6.0%
Economic Capital Ratio	147%